The company uses induced pluripotent stem cells (iPSC) to create vasculogenic cells that can restore function to tissues with restricted blood flow. Vascugen's therapies have the potential to treat cardiovascular, solid tumor, and other indications. The company has an integrated manufacturing facility for early-stage clinical manufacture of its products, and its lead product is an allogeneic vasculogenic cell that can create new blood vessels in oxygen-starved tissues. Using iPSCs, Vascugen can produce off-the-shelf, cryopreserved doses at scale, with the aim of revolutionizing the standard of care for patients suffering from severe conditions caused by restricted blood flow.